Rhabdomyolysis After Intravenous Iron Sucrose Infusion During Pregnancy

Ge, Christina; Reyes, Jessica Wolpaw; Queenan, Ruth Anne; Gherman, Robert B.

doi:10.1097/aog.0000000000005157

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2017 trial conducted in India by Sharma et al demonstrated the superiority of single-dose FCM over iron sucrose [69]. However, these formulations have been associated with adverse outcomes such as rhabdomyolysis with multiple infusions of iron sucrose and high rates of hypophosphatasemia with FCM [70,71]. The clinical relevance of hypophosphatemia with a single infusion of 1 g of iron is presently being studied.…”

Section: Intravenous Iron As a Treatment For Iron Deficiency And Iron...mentioning

confidence: 99%

Is It Time to Alter the Standard of Care for Iron Deficiency/Iron Deficiency Anemia in Reproductive-Age Women?

Bellad,

Patted,

Derman

2024

Biomedicines

View full text Add to dashboard Cite

Two billion people worldwide suffer from anemia, with reproductive-age women being disproportionately affected. Iron plays a crucial role in cellular function and impacts cognition, physical function, and quality of life. Iron deficiency (ID) and iron deficiency anemia (IDA) are associated with adverse effects on pregnancy and fetal development. Oral iron supplementation has been the standard treatment for decades, often producing sub-optimal outcomes. Many babies are still being born with ID and suffer adverse sequelae due to inadequate iron levels in the mothers. Is it time to consider a broad scale-up of parenteral iron as a new standard of care?

show abstract

Section: Intravenous Iron As a Treatment For Iron Deficiency And Iron...mentioning

confidence: 99%

Is It Time to Alter the Standard of Care for Iron Deficiency/Iron Deficiency Anemia in Reproductive-Age Women?

Bellad,

Patted,

Derman

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…4 In this month's issue of Obstetrics & Gynecology, two articles (see pages 1049 and 1052) report cautionary and reassuring outcomes associated with the use of IV iron. 5,6 The former is a case report of rhabdomyolysis after a second IV dose of iron sucrose. Iron sucrose, with a small carbohydrate carrier, releases more labile free iron than the newer formulations, which is believed to be responsible for the majority of adverse events reported with IV iron.…”

mentioning

confidence: 99%